ArticleMolecular therapy. Methods & clinical development2025
Establishment of a novel human amniotic epithelial-derived cell line, HAT, for high-yield AAV vector production.
Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Manufacture of adeno-associated virus vectors by a novel human-derived cell line HAT and comprehensive evaluation of the vectors.Molecular therapy. Advances · 2026Article
- Quantitative Analysis and Predictive Modeling of Nonspecific Adsorption of Recombinant Adeno-Associated Virus onto Solid Surfaces.Langmuir : the ACS journal of surfaces and colloids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy using adeno-associated virus (AAV) vectors has advanced remarkably in recent decades. However, efficient AAV vector production remains challenging despite extensive efforts to optimize the commonly used HEK293 cells. Here, we describe a novel host cell line tailored for AAV vector production. Human amniotic epithelial cell line for gene and cell therapy (HAT) was generated by introducing adenovirus type 5 E1 genes into primary cells isolated from placental amnion after cesarean section. HAT cells were adapted to suspension culture conditions in a serum-free, chemically defined medium and subsequently single-cell-cloned to support future industrial applications. HAT cells exhibited robust proliferation and AAV productivity. Quality assessments revealed that HAT-produced AAV2 and AAV8 vectors had overall product quality attributes comparable to those from HEK293 cells. They were characterized by efficient genome packaging and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.